Published • loading... • Updated
Swiss Windward Bio adds US$165m to its Chinese pipeline - European Biotechnology Magazine
Summary by European-biotechnology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Swiss Windward Bio adds US$165m to its Chinese pipeline - European Biotechnology Magazine
Basel-based Windward Bio did it again and has raised another three-digit millions - $165 million to be exact – to advance a pipeline of long-acting immunology therapies—much of it sourced through in-licensing deals with Chinese partners. Its lead candidate, WIN378, is moving into Phase III, with first clinical readouts expected from 2026. The post Swiss Windward Bio adds US$165m to its Chinese pipeline appeared first on European Biotechnology Ma…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
